Luna R C P, de Oliveira Y, Lisboa J V C, Chaves T R, de Araújo T A M, de Sousa E E, Miranda Neto M, Pirola L, Braga V A, de Brito Alves J L
Departamento de Nutrição, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, PB, Brasil.
INSERM U1060, Lyon 1 University, Oullins, France.
Braz J Med Biol Res. 2018 Oct 18;51(12):e7437. doi: 10.1590/1414-431X20187437.
Pulmonary arterial hypertension (PAH), characterized by localized increased arterial blood pressure in the lungs, is a slow developing long-term disease that can be fatal. PAH is characterized by inflammation, vascular tone imbalance, pathological pulmonary vascular remodeling, and right-sided heart failure. Current treatments for PAH are palliative and development of new therapies is necessary. Recent and relevant studies have demonstrated that epigenetic processes may exert key influences on the pathogenesis of PAH and may be promising therapeutic targets in the prevention and/or cure of this condition. The aim of the present mini-review is to summarize the occurrence of epigenetic-based mechanisms in the context of PAH physiopathology, focusing on the roles of DNA methylation, histone post-translational modifications and non-coding RNAs. We also discuss the potential of epigenetic-based therapies for PAH.
肺动脉高压（PAH）的特征是肺部局部动脉血压升高，是一种发展缓慢的长期疾病，可能会致命。PAH的特征包括炎症、血管张力失衡、病理性肺血管重塑和右心衰竭。目前PAH的治疗是姑息性的，因此有必要开发新的治疗方法。最近的相关研究表明，表观遗传过程可能对PAH的发病机制产生关键影响，并且可能是预防和/或治愈这种疾病的有前景的治疗靶点。本综述的目的是总结基于表观遗传学的机制在PAH生理病理学中的发生情况，重点关注DNA甲基化、组蛋白翻译后修饰和非编码RNA的作用。我们还讨论了基于表观遗传学的PAH治疗的潜力。
